Brean Capital started coverage on shares of Cytosorbents Corp (OTCMKTS:CTSO) in a research report sent to investors on Tuesday morning. The firm issued a buy rating and a $24.00 price target on the stock.
Separately, Maxim Group restated a buy rating on shares of Cytosorbents Corp in a research note on Wednesday, June 15th.
Cytosorbents Corp (OTCMKTS:CTSO) opened at 6.46 on Tuesday. The firm’s 50-day moving average is $5.64 and its 200-day moving average is $4.77. Cytosorbents Corp has a 52-week low of $3.11 and a 52-week high of $8.10. The firm’s market capitalization is $164.32 million.
Cytosorbents Corp (OTCMKTS:CTSO) last released its quarterly earnings results on Tuesday, August 9th. The company reported ($0.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.09) by $0.03. The company earned $1.90 million during the quarter, compared to analyst estimates of $2.18 million. On average, equities analysts expect that Cytosorbents Corp will post ($0.39) earnings per share for the current year.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. increased its position in Cytosorbents Corp by 1.0% in the second quarter. Vanguard Group Inc. now owns 537,707 shares of the company’s stock valued at $2,447,000 after buying an additional 5,446 shares during the last quarter. Raymond James & Associates increased its position in Cytosorbents Corp by 318.6% in the second quarter. Raymond James & Associates now owns 324,603 shares of the company’s stock valued at $1,477,000 after buying an additional 247,052 shares during the last quarter. Advisor Group Inc. purchased a new position in Cytosorbents Corp during the second quarter valued at $1,372,000. Douglass Winthrop Advisors LLC purchased a new position in Cytosorbents Corp during the second quarter valued at $321,000. Finally, BlackRock Fund Advisors increased its position in Cytosorbents Corp by 39.3% in the second quarter. BlackRock Fund Advisors now owns 53,915 shares of the company’s stock valued at $245,000 after buying an additional 15,203 shares during the last quarter.
About Cytosorbents Corp
CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.
Receive News & Ratings for Cytosorbents Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents Corp and related companies with MarketBeat.com's FREE daily email newsletter.